NCT02856477
Terminated
N/A
Pharmacogenetic in the Therapeutic Strategy in Depressed Elderly
ConditionsDepression
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Depression
- Sponsor
- Centre Hospitalier Universitaire de Besancon
- Enrollment
- 28
- Locations
- 1
- Primary Endpoint
- patient remission
- Status
- Terminated
- Last Updated
- 9 years ago
Overview
Brief Summary
The study aims to assess the therapeutic benefits of the adaptation of the antidepressant dose to the metabolic capacity (cytochrome P450 2D6) of elderly depressed patients.
Therapeutic benefits are evaluated through the enhancement of efficiency, decrease of the action time and the after effects.
Investigators
Eligibility Criteria
Inclusion Criteria
- •current major depressive disorder
- •antidepressant treatment
Exclusion Criteria
- •dextromethorphan contra-indication
- •other psychiatric disorder
- •kidney failure
- •liver failure mini mental State Examination (MMSE)\<18
Outcomes
Primary Outcomes
patient remission
Time Frame: 6 months
remission is defined by a Montgomery and asberg depression rating (MADRS) score\<10.
Study Sites (1)
Loading locations...
Similar Trials
Completed
N/A
Pharmacogenetic-Directed Treatment for Major DepressionDepressionNCT01261364Assurex Health Inc.50
Completed
N/A
A Pharmacokinetic/Pharmacodynamic Genetic Variation Treatment Algorithm Versus Treatment As Usual for Management Of DepressionDepressionMood DisorderBipolarNCT02189057Mayo Clinic160
Unknown
N/A
Predict Antidepressant Responsiveness Using PharmacogenomicsDepressionDepressive SymptomsNCT01228357Samsung Medical Center1,000
Unknown
Phase 4
Pharmacogenomics Studies of AntidepressantsMajor Depressive DisorderAntidepressive AgentsPharmacogeneticsVenlafaxineFluoxetineNCT01204086National Cheng-Kung University Hospital200
Completed
N/A
Clinical Pharmacogenomics of Antidepressant ResponseDepressionNCT00384020National Health Research Institutes, Taiwan402